Heidelberg Pharma AG
HPHA
Rank in Stocks
#19388
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.26
Last synced: 2026-11-18
Market Cap
$101.72M
Change (1 day)
-0.61%
Change (1 year)
-33.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Heidelberg Pharma AG (HPHA)
Category
Healthcare
P/S ratio for Heidelberg Pharma AG (HPHA)
P/S ratio as of November 2026 TTM: 10.49
According to Heidelberg Pharma AG's latest financial reports and stock price, its current price-to-sales ratio (TTM) is 10.49. At the end of 2025 the company had a P/S ratio of 92.22.
P/S ratio history for Heidelberg Pharma AG from 2006 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 10.49 | -88.62% |
| 2025 | 92.22 | 464.73% |
| 2024 | 16.33 | 25.19% |
| 2023 | 13.04 | 13.39% |
| 2022 | 11.50 | -88.04% |
| 2021 | 96.22 | 425.35% |
| 2020 | 18.32 | 114.73% |
| 2019 | 8.53 | -60.95% |
| 2018 | 21.84 | 5.77% |
| 2017 | 20.65 | -45.90% |
| 2016 | 38.17 | 470.94% |
| 2015 | 6.69 | 46.81% |
| 2014 | 4.55 | 31.04% |
| 2013 | 3.48 | 127.52% |
| 2012 | 1.53 | -96.38% |
| 2011 | 42.20 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | 6.51 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.51 | 0.19% |
US
|
|
| 35.79 | 241.12% |
US
|
|
| 4.19 | -60.07% |
AU
|
|
| 6.63 | -36.80% |
BE
|
|
| 13.60 | 29.59% |
NL
|
Questions about Heidelberg Pharma AG's P/S ratio
What is Heidelberg Pharma AG's P/S ratio?
Heidelberg Pharma AG's P/S ratio is 10.49, as of Nov 2026.
What was Heidelberg Pharma AG's P/S ratio in 2025?
In 2025, Heidelberg Pharma AG's P/S ratio was 92.22, compared with 16.33 in 2024.
How has Heidelberg Pharma AG's P/S ratio changed since 2020?
From 2020 to 2025, Heidelberg Pharma AG's P/S ratio was highest in 2021 (96.22) and lowest in 2022 (11.50).
How does Heidelberg Pharma AG's P/S ratio compare with similar companies?
Heidelberg Pharma AG's P/S ratio (10.49) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.